Spiro-oxindole MDM2 Antagonists for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer therapies face challenges due to cancer cells' resistance to apoptosis, primarily attributed to defects in the apoptotic machinery, which is often associated with the p53-MDM2 interaction, where existing inhibitors, including peptide-based and small molecule compounds, suffer from poor cell permeability and limited bioavailability.
Innovation Solution
Development of spiro-oxindole-based compounds that inhibit the p53-MDM2 interaction, specifically designed to enhance cell permeability and bioavailability, thereby sensitizing cells to apoptosis and cell cycle arrest, and potentially used in combination with other anticancer agents to increase therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide-based inhibitors of MDM2 are used, then high-affinity inhibition of the p53-MDM2 interaction is achieved, but cell permeability and in vivo bioavailability are poor
Solution Approach 1:
The patent transforms the peptide-based inhibitor into a small molecule compound by fundamentally changing the chemical parameters and structural characteristics. The spiro-oxindole core structure with specific substituents (R1-R6 groups) creates a drug-like molecule that maintains MDM2 binding affinity while achieving oral bioavailability and cell permeability, directly resolving the contradiction between high-affinity inhibition and cell permeability
Solution Approach 2:
The patent creates a small molecule copy that mimics the binding interface and interaction mechanism of peptide-based inhibitors. By copying the essential pharmacophore features and optimizing the molecular structure, the invention achieves similar or superior inhibitory activity while overcoming the limitations of peptide-based approaches through the use of a non-peptide chemical scaffold
2Ease of operation
If small molecule inhibitors of p53-MDM2 interaction are developed, then cell permeability is improved, but potency and selectivity are limited
Solution Approach 1:
The patent applies local quality by optimizing specific regions of the molecule (R1-R6 substituents) to enhance different properties: certain groups improve cell permeability while others maintain binding potency. The spiro-oxindole core provides the essential binding interaction, while peripheral substituents are tailored to optimize pharmacokinetic properties, achieving both cell permeability and potency simultaneously
3Reliability
If existing MDM2 inhibitors are used, then apoptosis resistance is addressed, but therapeutic window is limited due to toxicity to normal cells
Solution Approach 1:
The patent uses the spiro-oxindole compound as an intermediary that specifically disrupts the p53-MDM2 interaction in cancer cells, thereby sensitizing them to apoptosis-inducing therapies. The compound acts as a mediator that restores apoptotic sensitivity without directly killing normal cells, expanding the therapeutic window by selectively affecting cancer cell survival mechanisms
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.